RVPH Stock Price, Reviva Pharmaceuticals Holdings Quote, Chart

Market Summary

USD3.11+0.21

Delayedas of 30 Apr 2024, 03:05 pm

7.24%

RVPH Stock Price

View Fullscreen

RVPH RSI Chart

RVPH Valuation

Market Cap

81.0M

Price/Earnings (Trailing)

-2.06

EV/EBITDA

-1.47

Price/Free Cashflow

-2.86

MarketCap/EBT

-2.06

RVPH Price/Earnings (Trailing)

RVPH Profitability

Return on Equity

-686.53%

Return on Assets

-165.65%

Free Cashflow Yield

-34.98%

RVPH Fundamentals

RVPH Earnings

Earnings (TTM)

-39.3M

Earnings Growth (Yr)

-19.78%

Earnings Growth (Qtr)

7.31%

Breaking Down RVPH Revenue

52 Week Range

2.909.25

(Low)(High)

Last 7 days

-5.8%

Last 30 days

-23.0%

Last 90 days

-27.6%

Trailing 12 Months

-57.5%

How does RVPH drawdown profile look like?

RVPH Financial Health

Current Ratio

0

RVPH Investor Care

Shares Dilution (1Y)

36.51%

Tracking the Latest Insider Buys and Sells of Reviva Pharmaceuticals Holdings

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Nov 18, 2022	patel purav	bought	14,070	4.69	3,000	-
Sep 30, 2022	narayan prabhu	bought	83,000	1.66	50,000	chief financial officer
Jun 30, 2022	narayan prabhu	bought	60,670	1.2134	50,000	chief financial officer
Jun 01, 2021	vedanta partners, llc	bought	4,987,500	3.75	1,330,000	-
Dec 14, 2020	tenzing llc	acquired	-	-	197,500	-

Which funds bought or sold RVPH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-232,000	-	-%
Apr 25, 2024	Rosalind Advisors, Inc.	sold off	-100	-1,010,940	-	-%
Apr 19, 2024	Cutler Group LLC / CA	unchanged	-	-4,000	11,000	-%
Mar 15, 2024	B. Riley Wealth Advisors, Inc.	sold off	-100	-17,096	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	58.29	2,015,410	5,021,160	-%
Feb 26, 2024	Virtu Financial LLC	new	-	78,000	78,000	0.01%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	sold off	-100	-342,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	149,819	149,819	-%
Feb 15, 2024	Colony Group, LLC	new	-	623,000	623,000	0.01%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	1,059,420	1,059,420	-%

Are Funds Buying or Selling RVPH?

Are funds buying RVPH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RVPH

No. of Funds

Unveiling Reviva Pharmaceuticals Holdings's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2024	bhat laxminarayan	10.2%	2,885,678	SC 13D/A
Feb 14, 2024	tang capital partners lp	9.99%	3,098,615	SC 13G/A
Feb 14, 2024	armistice capital, llc	6.32%	1,764,000	SC 13G
Nov 30, 2023	vedanta partners, llc	9.0%	2,656,918	SC 13D/A
May 05, 2023	bhat laxminarayan	13.5%	2,811,545	SC 13D/A
Feb 14, 2023	tang capital partners lp	9.99%	2,266,229	SC 13G/A
Sep 12, 2022	vedanta partners, llc	12.0%	2,656,918	SC 13D/A
Jan 19, 2021	tenzing llc	27.24%	2,662,250	SC 13D/A
Jan 19, 2021	tenzing llc	22.98%	2,121,750	SC 13D/A
Jan 19, 2021	tenzing llc	6.09%	0	SC 13D/A

Recent SEC filings of Reviva Pharmaceuticals Holdings

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	8-K	Current Report
Apr 15, 2024	8-K	Current Report
Apr 15, 2024	8-K	Current Report
Apr 15, 2024	10-K	Annual Report
Apr 02, 2024	NT 10-K	NT 10-K
Feb 16, 2024	SC 13D/A	13D - Major Acquisition
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report
Feb 13, 2024	424B4	Prospectus Filed
Feb 13, 2024	EFFECT	EFFECT

Peers (Alternatives to Reviva Pharmaceuticals Holdings)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.6B	6.8B	4.75%	-16.01%	-9.05	6.23	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.40%	-26.02%	-42.16	10.15	76.23%	61.08%
BMRN	15.4B	2.5B	-5.97%	-14.48%	74.78	6.22	13.74%	186.89%
INCY	11.8B	3.7B	-7.74%	-29.36%	19.75	3.19	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.63%	-42.67%	-10.91	14.55	425.83%	18.94%
BBIO	4.5B	-	-17.63%	75.41%	-6.86	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.66%	3.02%	-14.59	12.9	440.80%	-27.84%
ARWR	2.9B	240.7M	-19.13%	-34.68%	-9.65	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-7.52%	-19.83%	-45.97	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.45%	-4.33%	25.14	4.51	85.90%	-14.05%
NVAX	600.4M	983.7M	-10.25%	-44.07%	-1.1	0.61	-50.36%	17.16%
CRBP	374.0M	881.7K	-9.17%	305.92%	-8.38	466.16	-77.61%	-5.33%
INO	268.8M	4.9M	-17.15%	24.46%	-1.99	55.23	-54.97%	51.71%
IBIO	5.8M	2.1M	-59.11%	53.70%	-0.21	2.14	-13.45%	66.37%

Reviva Pharmaceuticals Holdings News

Latest updates

Reviva Pharmaceuticals Holdings Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q4	2019Q3	2019Q2
Assets	340.0%	23,700	5,387	11,842	12,902	18,924	24,041	20,643	25,268	31,404	33,894	36,535	6,658	8,762	34,694	34,478	34,459	61,022	63,747	66,473	66,270	65,989
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	44.00	38.00	240	139	-	150	250	338
Cash Equivalents	370.0%	23,367	4,972	11,152	11,256	18,520	23,192	19,420	23,421	29,688	33,492	35,801	5,644	8,760	37.00	16.00	198	69.00	193*	134	211	274
Liabilities	29.3%	17,982	13,906	10,221	7,117	6,607	3,681	4,583	3,907	2,718	1,625	2,014	2,142	3,297	5,049	4,375	3,840	3,263	6,814	2,314	2,248	2,241
Current Liabilities	31.8%	17,175	13,033	9,208	6,560	6,040	3,576	4,477	3,623	2,345	974	1,163	1,101	1,333	860	736	501	300	-	100	34.00	28.00
Short Term Borrowings	-100.0%	-	223	223	668	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	144.6%	5,719	-12,810	1,621	5,785	12,316	20,360	16,060	21,361	28,686	32,269	34,521	4,516	5,466	5,000	5,000	5,000	5,000	-	5,000	5,000	5,000
Retained Earnings	-11.3%	-134,400	-120,707	-110,216	-97,773	-91,171	-83,052	-79,500	-74,196	-66,831	-63,147	-60,867	-59,259	-58,310	172	520	1,036	1,192	-54,526	1,324	1,187	913
Additional Paid-In Capital	24.9%	140,070	112,186	111,836	103,557	103,486	103,410	95,597	95,557	95,517	95,415	95,387	63,775	63,775	-	-	-	-	18,645	-	-	-
Shares Outstanding	35.2%	27,919	20,650	22,650	20,452	20,447	18,737	18,467	18,467	14,433	18,456	10,961	9,232	-	-	-	-	-	-	-	-	-
Float	-	103,700	-	-	-	-	-	11,200	-	-	-	41,400	-	-	-	-	-	-	-	-	59,058	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q4	2020Q3	2020Q3	2020Q2	2020Q2	2020Q1	2020Q1	2019Q4
Cashflow From Operations	-43.6%	-8,876	-6,179	-5,317	-7,951	-4,690	-4,001	-4,001	-6,266	-3,902	-2,309	-1,340	-3,116	-3,545	-	-823	-	-379	-35.46	-60.66	-	-39.70
Share Based Compensation	11.5%	391	350	2,621	52.00	57.00	41.00	40.00	40.00	62.00	28.00	17.00	-	-	-	-	-	-	-	-	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-206	-	-210	-	26,773	-	5,702	-
Cashflow From Financing	-	27,272	-	5,213	687	19.00	7,774	-	70*	98.00	-	31,497	-	38,695	-	27,793	-	27,219	-26,608	230	-	100
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	109	-	-	-	26,984	-	6,269	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RVPH Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses
Research and development	$ 31,419,817	$ 22,870,024
General and administrative	8,083,819	5,358,734
Total operating expenses	39,503,636	28,228,758
Loss from operations	(39,503,636)	(28,228,758)
Other income (expense)
Loss on remeasurement of warrant liabilities	(239,216)	(194,709)
Interest and other income, net	498,964	182,802
Total other income (expense), net	259,748	(11,907)
Loss before provision for income taxes	(39,243,888)	(28,240,665)
Provision for income taxes	(16,949)	(20,777)
Net loss	$ (39,260,837)	$ (28,261,442)
Net loss per share:
Basic and diluted (in dollars per share)	$ (1.65)	$ (1.45)
Weighted average shares outstanding
Basic and diluted (in shares)	23,798,203	19,516,479

RVPH Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents	$ 23,367,456	$ 18,519,856
Prepaid expenses and other current assets	332,932	403,819
Total Assets	23,700,388	18,923,675
Liabilities
Accounts payable	3,849,108	3,520,271
Accrued expenses and other current liabilities	11,966,812	5,578,374
Accrued compensation	958,607	564,646
Other accrued liabilities	400,490	298,699
Total current liabilities	17,175,017	9,961,990
Warrant liabilities	806,655	567,439
Total Liabilities	17,981,672	10,529,429
Stockholders' Equity
Common stock, par value of $0.0001; 115,000,000 shares authorized; 27,918,560 and 20,447,371 shares issued and outstanding as of December 31, 2023 and 2022, respectively	2,792	2,045
Preferred Stock, par value of $0.0001; 10,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2023 and 2022	0	0
Additional paid-in capital	140,070,172	103,485,612
Accumulated deficit	(134,354,248)	(95,093,411)
Total stockholders' equity	5,718,716	8,394,246
Total Liabilities and Stockholders' Equity	$ 23,700,388	$ 18,923,675

About Reviva Pharmaceuticals Holdings

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentionÃ‚â€“deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino, California.

CEO	Dr. Laxminarayan Bhat Ph.D.
WEBSITE	https://revivapharma.com
INDUSTRY	Biotechnology
EMPLOYEES	10

Reviva Pharmaceuticals Holdings Frequently Asked Questions

What is the ticker symbol for Reviva Pharmaceuticals Holdings? What does RVPH stand for in stocks?

RVPH is the stock ticker symbol of Reviva Pharmaceuticals Holdings. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Reviva Pharmaceuticals Holdings (RVPH)?

As of Mon Apr 29 2024, market cap of Reviva Pharmaceuticals Holdings is 80.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RVPH stock?

You can check RVPH's fair value in chart for subscribers.

What is the fair value of RVPH stock?

You can check RVPH's fair value in chart for subscribers. The fair value of Reviva Pharmaceuticals Holdings is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Reviva Pharmaceuticals Holdings is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RVPH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Reviva Pharmaceuticals Holdings a good stock to buy?

The fair value guage provides a quick view whether RVPH is over valued or under valued. Whether Reviva Pharmaceuticals Holdings is cheap or expensive depends on the assumptions which impact Reviva Pharmaceuticals Holdings's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RVPH.